Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ricolinostat (Primary)
- Indications Diabetic neuropathies
- Focus Proof of concept; Therapeutic Use
- Sponsors Regenacy Pharmaceuticals
- 18 Sep 2023 Status changed from active, no longer recruiting to completed.
- 06 Jul 2022 Planned End Date changed from 15 Jun 2022 to 15 Feb 2023.
- 06 Jul 2022 Planned primary completion date changed from 30 Dec 2021 to 31 Oct 2022.